ArticleBreast (Edinburgh, Scotland)2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
Article in Breast (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03275311 (Epidemiological Strategy and Medical Economic), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A systematic literature review of prognostic factors in patients with HR+/HER2- advanced breast cancer in Japan.Japanese journal of clinical oncology · 2021Pooled it
- A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer.Journal of cancer research and clinical oncology · 2025Trial
- A Nomogram and Risk Classification System Predicting the Prognosis of Patients with De Novo Metastatic Breast Cancer Undergoing Immediate Breast Reconstruction: A Surveillance, Epidemiology, and End Results Population-Based Study.Current oncology (Toronto, Ont.) · 2023Trial
- Quality of Life in Adults With Metastatic Breast Cancer: The Impact of Between- and Within-Person Changes in Symptoms and Positive Affect.Cancer medicine · 2026Article
- Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT.Annals of nuclear medicine · 2026Article
- Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment.International journal of cancer · 2026Article
- Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.BMC cancer · 2026Article
- Metastatic Recurrence of Breast Cancer by Stage and Molecular Profile: A Population-Based Study Among Italian Women.Cancer medicine · 2026Article
- The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.NPJ breast cancer · 2025Article
- A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study.Communications medicine · 2025Article
- Article
- Clinical profile and outcomes of young women with denovo-metastatic breast cancer: real-world data from a tertiary care centre in India.Ecancermedicalscience · 2025Article
- Clinicopathological Evaluation of Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Progressing on Endocrine Treatment: A Real-World Retrospective Study from a Regional Cancer Center.South Asian journal of cancer · 2025Article
- Senescent cells promote breast cancer cells motility by secreting GM-CSF and bFGF that activate the JNK signaling pathway.Cell communication and signaling : CCS · 2024Article
- Assessing Trends in Hospitalizations for Breast Cancer among Women in Korea: A Utilization of the Korea National Hospital Discharge In-depth Injury Survey (2006-2020).Journal of epidemiology and global health · 2024Article
- Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.Breast cancer research : BCR · 2024Article
- Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices.Future oncology (London, England) · 2024Article
- Prognostic factors for hormone receptor-positive breast cancer with liver metastasis and establishment of novel nomograms for prediction: a SEER-based study.Translational cancer research · 2023Article
- Article
- The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 17 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYoung age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (<40, 40 to 60 and > 60 years(y)).
methodsESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014.
resultsAmong 14 403 women included, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were <40, 40-60 and > 60 y respectively. Pts <40 had significantly more aggressive presentations than other age groups: more frequent HER2+ (25.7 vs 15.3% in >60y) and triple negative subtypes (27.4 vs 14.6% in >60y), and more frequent visceral involvement (36.3 vs 29.8% in >60y). At a median follow-up of 48 months, median OS differed across age groups: 38.8, 38.4 and 35.6 months for pts <40, 40-60 and > 60y, respectively (p < 0.0001). Compared to pts <40y, older pts had a statistically significant higher risk of death (all causes of death included), although of limited clinical value (HR = 1.1, IC 95%:1.01-1.20). There was a significant trend for better OS in pts <40y with HER2+ and luminal diseases. A possible explanation is a greater use of anti-Her2 therapies as first-line treatments: 86.6, 81.9 and 74.9% for pts <40, 40-60 and > 60y, respectively (p < 0.0001).
conclusionAlthough young age seems associated with more aggressive presentations at diagnosis of MBC, it has no deleterious effect on OS in this large series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.